Bristol Myers Squibb Co is a general drug manufacturer company located in New York, United States, which is part of the Healthcare sector, and is traded under the ticker BMY on the NYSE exchange.
Bristol Myers Squibb Co stock last closed at $57.00, down 0.84% from the previous day, and has decreased 6.63% in one year. It has underperformed other stocks in the Drug Manufacturers - General industry by 0.2 percentage points. Bristol Myers Squibb Co stock is currently +34.05% from its 52-week low of $42.52, and -9.36% from its 52-week high of $62.89.
As of Mar 23, 2026, there are 2.04B BMY shares outstanding. The market value of BMY is $116.08B. In the last 24 hours, 10.13M BMY shares were traded.
You will need an online brokerage account in order to access the NYSE market and buy BMY stock.
We believe that eToro is the best online stock brokerage. eToro gives you:
Get $10 towards your share purchase by creating an account with eToro now. This offer is only for US users.
Open eToro AccountNow that you've chosen your brokerage, you'll need to fill out some personal details so you are able to invest in BMY stock today.
Now that you have filled out your info on the best stock investing app, your next step is to transfer the money for your investment:
Watch the video below for more details depositing money into your new brokerage account.
Once you have decided on the best place to buy Bristol Myers Squibb Co stock, it's crucial to evaluate their stock prior to investing, so you can understand the risk as well as the upside.
WallStreetZen was built to help part-time investors perform more in-depth fundamental analysis quickly.
You can see all of the due diligence checks on BMY's stock page.
Analysts use many financial metrics, analyses, models, and charts to gauge BMY's fair value.
Using relative valuations ratios:
You can access more valuation research on BMY's stock here.
Out of 14 Equities analysts who monitor BMY, the consensus analyst rating on BMY is a Buy
It's important to keep in mind that analyst ratings are not recommendations, nor are they financial advice.
Mohit Bansal, a top 15% analyst from Wells Fargo maintains BMY with a hold rating and raises their BMY price target from $55.00 to $60.00, on Feb 6, 2026.
Seamus Fernandez, a top 2% analyst from Guggenheim maintains BMY with a strong buy rating and raises their BMY price target from $62.00 to $72.00, on Feb 6, 2026.
Andrew Baum, a top 18% analyst from Citigroup maintains BMY with a hold rating and raises their BMY price target from $53.00 to $60.00, on Jan 27, 2026.
David Risinger, a top 9% analyst from Leerink Partners maintains BMY with a buy rating and raises their BMY price target from $54.00 to $60.00, on Jan 13, 2026.
Leerink Partners's David Risinger raised their price target on Bristol Myers Squibb Co (NYSE: BMY) by 11.1% from $54 to $60 on 2026/01/13. The analyst maintained their Buy rating on the stock.
Hiking their price target in a note previewing Bristol Myers Squibb's 2026, Risinger cited the overview Bristol Myers Squibb provided of its pipeline readouts to watch in 2026 and beyond at the J.P. Morgan Healthcare Conference.
Having assessed the presentation, the analyst said "significant pipeline optionality" is visible in 2026, offering "additional stock price upside potential."
Risinger detailed that Bristol Myers Squibb expects 12 registrational data readouts from 8 assets this year, most of which represent significant new launch opportunities in future years.
Investors heavily discount most pipeline candidates, meaning significant upside if some cards come up aces, the analyst added.
Louise Chen, a top 17% analyst from ScotiaBank maintains BMY with a hold rating and raises their BMY price target from $53.00 to $60.00, on Jan 9, 2026.
You can dig deeper into what analysts are projecting on the Bristol Myers Squibb Co stock forecast page.
Last year, BMY earnings were $7.05B. Over the last 4 year, BMY's earnings have grown by 2.45% per year. This was slower than the Drug Manufacturers - General industry average of 19.56%.
Last year, BMY revenue was $48.19B. Over the past five year, BMY's revenue has grown by 2.54% per year. This was slower than the Drug Manufacturers - General industry average of 9.96%.
You can analyze BMY's earnings and revenue performance here.
In the last year, executives and large shareholders at BMY have sold more shares than they have bought.
David V. Elkins, EVP Chief Financial Officer of BMY, was the latest BMY insider to sell. They sold $173,354.79 worth of BMY stock on Mar 10, 2026.
Dig into more about who owns BMY shares here.
Bristol Myers Squibb Co pays a dividend of 3.28%, compared to the Drug Manufacturers - General industry's average dividend yield of 2.83%. If you owned $1,000 worth of BMY stock, you would have received $32.81 in the past 12 months.
Bristol Myers Squibb Co dividend payments have consistently grown over the past decade and have remained stable.
Dig into more analysis about Bristol Myers Squibb Co dividend yield and history here.
One of the major reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to learn what other traders have to say.
You have two main options:
Hit the Open Trade button and your broker will execute your order.
If you want additional info about investing in stocks on eToro, click the helpful video below:
Now that you own some BMY stock, you'll want to stay up-to-date on your company.
Create a watchlist to track the latest developments regarding your BMY stock.
To summarize, here are the 6 steps you need to take to buy Bristol Myers Squibb Co stock right now:
If you need a brokerage, eToro is our favorite option.
Get Started with eToro TodayIf you would like to monitor your investment in Bristol Myers Squibb Co, create a watchlist today.